Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

AMPK and Friends: Central Regulators of β Cell Biology

(2018) Jillian L. Rourke et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

(2018) Naveed Sattar et al.   DIABETOLOGIA

Emerging roles of SIRT1 in fatty liver diseases

(2017) Ren-Bo Ding et al.   International Journal of Biological Sciences

Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models

(2017) Shengnan Sun et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association

(2017) Seung-Hyun Ko et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

(2016) Yasushi Honda et al.   PLoS One

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

(2016) Chikara Komiya et al.   PLoS One

Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice

(2015) Atsuo Tahara et al.   ARCHIVES OF PHARMACAL RESEARCH

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes

(2015) Karen Whalen et al.   CLINICAL THERAPEUTICS

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

(2015) Yuka Hayashizaki-Someya et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Voglibose administration regulates body weight and energy intake in high fat-induced obese mice

(2014) Hyun Ju Do et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2014) André J. Scheen   DRUGS

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

(2014) Masanori Yokono et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients with Type 2 Diabetes

(2014) Jaime A. Davidson et al.   POSTGRADUATE MEDICINE

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

(2014) M Suzuki et al.   Nutrition & Diabetes

Obesity and Liver Disease

(2013) Kathleen E. Corey et al.   Clinics in Liver Disease

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease

(2013) Yasar Colak et al.   MEDICAL SCIENCE MONITOR

Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data

(2013) Eiji Kurosaki et al.   PHARMACOLOGY & THERAPEUTICS

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

(2012) Naga Chalasani et al.   HEPATOLOGY

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

(2012) Ele Ferrannini et al.   Nature Reviews Endocrinology

SREBPs: metabolic integrators in physiology and metabolism

(2011) Tae-Il Jeon et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Role of Sirtuin 1 in metabolic regulation

(2010) Jose P. Silva et al.   DRUG DISCOVERY TODAY

SGLT2 inhibition — a novel strategy for diabetes treatment

(2010) Edward C. Chao et al.   NATURE REVIEWS DRUG DISCOVERY

Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1–FOXO1 signaling pathway

(2009) Guang-Li Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Sirtuins regulate key aspects of lipid metabolism

(2009) David J. Lomb et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes

(2009) Shin-ichiro Imai   Frontiers in Bioscience-Landmark

SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase

(2008) Xiuyun Hou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY